Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel ...
Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results